Establishment Labs Holdings Inc.

NASDAQ•ESTA

CEO: Mr. Juan Jose Chacon Quiros

セクター: Healthcare

業種: Medical - Devices

上場日: 2018-07-19

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

連絡先情報

Building B15 and 25, Coyol Free Zone, Alajuela, Costa Rica

506-2434-2400

www.establishmentlabs.com

時価総額

$1.84B

PER (TTM)

-36.5

23.7

配当利回り

52週高値

$83.31

52週安値

$28.67

52週レンジ

63%

順位59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

9年ファンダメンタル

弱い • 2.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2017-2025

財務ダッシュボード

Q4 2025 データ

売上高

$64.62M+0.00%

直近4四半期の推移

EPS

-$0.09+0.00%

直近4四半期の推移

フリーCF

-$2.43M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth Post-Approval Revenue reached $211.1M USD, increasing 27.2% driven by US market penetration post-approval.

US Market Sales Surge US market sales reached $45.6M USD for the year, following September 2024 FDA approval.

Gross Margin Improvement Gross margin increased to 69.3% from 66.0% due to higher selling prices in the United States.

Net Loss Significantly Narrows Net loss significantly narrowed to $51.1M USD, an improvement from the $84.6M USD loss reported previously.

リスク要因

Sole Silicone Supplier Risk Reliance on sole silicone supplier Avantor presents risk as they plan to not automatically renew the supply agreement.

Continued Operating Losses Company incurred losses to date; achieving profitability depends on Motiva Implants commercial success and scaling.

Rising Operating Expenses Operating expenses rose significantly, with SG&A increasing 18.1% to $165.1M USD, impacting cost control.

Implant Safety Scrutiny Negative publicity and safety concerns regarding breast implants could harm reputation and reduce overall market demand.

見通し

Preservé US Market Expansion Preservé launch continues through 2025, targeting a full commercial launch in the United States expected in 2026.

Elevated R&D Spending R&D expenses remain elevated for the decade-long post-approval study and advancing new product pipeline initiatives.

New CEO Strategy Execution New CEO appointed in May 2025; focus remains on executing US strategy and long-term growth priorities.

Future Capital Requirements Future capital needs depend on market adoption rates and managing significant ongoing regulatory compliance costs.

同業比較

売上高 (TTM)

AHCO

$2.84B

+7.4%

TDOC

$2.53B

-1.5%

IART

$1.64B

+1.5%

粗利益率 (最新四半期)

IMTX

100.0%

+0.0pp

ATAI

100.0%

+0.0pp

TSHA

94.5%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
SYRE	$3.82B	-141.1	-29.4%	0.0%
NEOG	$1.99B	-3.3	-29.0%	0.0%
ZYME	$1.94B	-24.3	-26.0%	5.3%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

16.0%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月5日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし